Get the Stockscreener App
6.67
1.21%
0.08
Vir Biotechnology Inc stock is traded at $6.67, with a volume of 1.21M.
It is up +1.21% in the last 24 hours and down -17.76% over the past month.
See More
Previous Close:
$6.59
Open:
$6.59
24h Volume:
1.21M
Relative Volume:
0.62
Market Cap:
$987.43M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.7015
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
-2.91%
1M Performance:
-17.76%
6M Performance:
-11.42%
1Y Performance:
-33.96%
1-Day Range:
$6.40
$6.76
1-Week Range:
$6.40
$7.22
52-Week Range:
$6.40
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
6.67 | 987.43M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.55 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.83 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
593.47 | 36.20B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.02 | 35.08B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
262.60 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - Stock Traders Daily
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
(VIR) Trading Signals - Stock Traders Daily
Morgan Stanley maintains $20 target on Vir Biotechnology stock By Investing.com - Investing.com Canada
Morgan Stanley maintains $20 target on Vir Biotechnology stock - Investing.com India
Vir Biotechnology enrolls first patient in late-stage study of its treatment for severe liver infection - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 Chronic Hepatitis Delta Trial -March 13, 2025 at 08:30 am EDT - Marketscreener.com
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire
Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com
SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Brokerages Set Vir Biotechnology, Inc. (NASDAQ:VIR) Price Target at $35.67 - Defense World
Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN
Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World
Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World
Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World
(VIR) On The My Stocks Page - Stock Traders Daily
HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World
Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance
7 Analysts Have This To Say About Vir Biotechnology - Benzinga
Decoding Vir Biotechnology Inc (VIR): A Strategic SWOT Insight - GuruFocus.com
Vir Biotechnology’s Transformative Year: Earnings Call Insights - TipRanks
Vir Biotechnology Becomes Oversold (VIR) - Nasdaq
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada
Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India
Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey
Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks
Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks
Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks
Vir Biotechnology, Inc. SEC 10-K Report - TradingView
Vir Biotechnology Inc (VIR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates - MSN
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results - BioSpace
Vir Biotechnology Reports 2024 Financial Results and Strategic Advances - TipRanks
Vir Biotechnology: Strong Financial Position and Promising Pipeline Justify Buy Rating - TipRanks
Earnings call transcript: Vir Biotech beats Q4 2024 forecasts, stock rises - Investing.com India
Vir Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vir Biotechnology reports Q4 EPS (76c), consensus (87c) - TipRanks
Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 11c - StreetInsider.com
Vir Biotechnology EVP vanina de Verneuil sells $48,590 in shares By Investing.com - Investing.com Australia
Vir Biotechnology CEO sells $152,407 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology's SVP sells shares worth $14,766 By Investing.com - Investing.com Canada
Vir Biotechnology EVP sells shares worth $133,935 By Investing.com - Investing.com Australia
Vir Biotechnology EVP sells shares worth $133,935 - Investing.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):